Skip to main
FGEN
FGEN logo

FibroGen (FGEN) Stock Forecast & Price Target

FibroGen (FGEN) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

FibroGen Inc. focuses on developing therapeutics for serious medical needs, generating most of its revenue through collaboration agreements, primarily in Europe and Japan. The anticipated extension of the company's cash runway significantly enhances its financial health, providing confidence amid challenging macroeconomic conditions. This strong cash position allows FibroGen to advance its clinical trials, particularly for FG-3246, without anticipated interruptions, which supports a favorable outlook for the company's growth and sustainability.

Bears say

FibroGen Inc's financial outlook is negatively influenced by several critical factors, including the potential for failed or inconclusive clinical trials that could hinder product development. The company also faces challenges in securing adequate funding, which is essential for progressing its product candidates, and may encounter dilutive capital raises that could further impact shareholder value. Additionally, the lack of commercial success and the risk of being delisted pose significant threats to the company's financial stability and growth prospects.

FibroGen (FGEN) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of FibroGen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About FibroGen (FGEN) Forecast

Analysts have given FibroGen (FGEN) a Strong Buy based on their latest research and market trends.

According to 1 analysts, FibroGen (FGEN) has a Strong Buy consensus rating as of Nov 9, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

FibroGen (FGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.